文献速递泌尿生殖腹部技术与安全PETCTMRDR

复发尿路上皮癌中18F-氟脱氧葡萄糖正电子发射断层显像/计算机断层显像与常规影像诊断准确性的比较:一项回顾性多中心研究

Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study.
PubMed 文献 · Abdom Radiol (NY) · 2018-01-01

这项回顾性国际多中心研究纳入287例原发肿瘤治疗后疑似复发的尿路上皮癌患者,评估FDG PET/CT诊断复发的敏感度94%、特异度79%;在198例有常规影像对比的患者中,PET/CT对膀胱癌和上尿路尿路上皮癌复发的敏感度、特异度及准确率均高于常规影像。

要点

  • PET/CT检测复发尿路上皮癌总体敏感度94%、特异度79%。
  • 膀胱癌复发检测敏感度95%高于上尿路尿路上皮癌的85%,特异度78%低于后者的85%。
  • PET/CT与常规影像一致性的K Cohen=0.426(p<0.001)。

核心结论

  • FDG PET/CT对识别复发尿路上皮癌具有高诊断准确性,尤其在膀胱癌患者中。
  • PET/CT对膀胱癌和上尿路尿路上皮癌的诊断准确性均优于常规影像。

研究设计与样本

  • 回顾性、国际多中心研究,共纳入287例原发肿瘤治疗后疑似复发的尿路上皮癌患者。
  • 纳入标准:已知膀胱癌和/或上尿路尿路上皮癌病史;原发肿瘤根治性治疗后PET/CT图像;PET/CT前3个月内完成常规影像(腹部增强CT或MRI,或全身增强CT加胸部X线,称为C.I.);有可用的参考标准(如组织学数据或随访影像)验证PET/CT所见。
  • 排除标准:其他腹部肿瘤、影像检查前和/或同期接受化疗、非尿路上皮组织学变异型。
  • 参考标准为组织学数据或随访影像等可用标准。

诊断标准与关键数值

  • PET/CT检测复发尿路上皮癌的敏感度94%(95%CI 91%~96%),特异度79%(95%CI 68%~88%)。
  • 膀胱癌 vs 上尿路尿路上皮癌:敏感度95% vs 85%,特异度78% vs 85%。
  • 198例有PET/CT与常规影像对照:两者结果阳性一致137例、阴性一致23例、不一致38例(常规影像阴性而PET/CT阳性20例,增强CT/MRI阳性而PET/CT阴性18例),K Cohen=0.426(p<0.001)。
  • PET/CT vs 常规影像检测复发膀胱癌和上尿路尿路上皮癌:敏感度94%(95%CI 90%~97%)vs 86%(95%CI 81%~92%),特异度79%(95%CI 67%~92%)vs 59%(95%CI 44%~74%),准确率91%(95%CI 87%~95%)vs 81%(95%CI 75%~86%)。

临床应用与阅片要点

  • 原文结论认为FDG PET/CT对识别复发尿路上皮癌具有高诊断准确性,尤其在膀胱癌患者中,且其准确性优于常规影像。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To determine the performance accuracy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) after primary tumor treatment for both bladder cancer (BC) and upper tract urothelial cancer (UTUC). To compare the accuracy of FDG PET/CT with that of contrast-enhanced-ceCT and magnetic resonance imaging (MRI).

METHODS: Data of patients with recurrent urothelial carcinomas (UC) after primary treatment were collected in a retrospective, international multicenter study. Inclusion criteria were (1) patients with a known history of UC in the BC and/or in the UTUC; (2) PET/CT images after curative intent treatment of the primary tumor; (3) conventional imaging modalities (abdominal ceCT or MRI, or total body ceCT, and chest X-ray: called C.I.) performed no more than 3 months from PET/CT; (4) available standard of reference (e.g., histological data or follow-up imaging modalities) for the validation of PET/CT findings. Exclusion criteria were other abdominal tumors, chemotherapy administration prior to and/or concomitant to imaging, and non-urothelial histologic variants. Sensitivities, specificities, positive, and negative predictive values were evaluated for all patients and separately for bladder and UTUC.

RESULTS: Overall, 287 patients were enrolled. Two-hundred thirteen patients underwent cystectomy (74.2%), 35 nephroureterectomy (12.2%), 31 both cystectomy + nephroureterectomy (10.8%), 5 both cystectomy + conservative treatment for UTUC (1.4%), and 3 (1%) other types of nephron-sparing treatments for UTUC. Neoadjuvant and adjuvant treatments were performed in 36 (12.5%) and 111 (38.7%) patients, respectively. Sensitivity and specificity (95% confidence intervals) of PET/CT for the detection of recurrent UC were 94% (91% to 96%) and 79% (68% to 88%), respectively. However, sensitivity was higher for BC than UTUC (95% vs. 85%) while specificity was lower in BC (78% vs. 85% for BC and UTUC, respectively). PET/CT and C.I. findings were available in 198 patients. The results were positively concordant in 137 patients, negatively concordant in 23 patients, and discordant in 38 patients (20 negative at C.I. vs. positive at PET/CT and 18 positives at ceCT/MRI vs. negative at PET/CT) (K Cohen = 0.426; p < 0.001). Sensitivities, specificities, and accuracies (95% confidence intervals) of PET/CT vs. C.I. for the detection of recurrent BC and UTUC were 94% (90% to 97%) vs. 86% (81% to 92%), 79% (67% to 92%) vs. 59% (44% to 74%), and 91% (87% to 95%) vs. 81% (75% to 86%), respectively.

CONCLUSIONS: FDG PET/CT has a high diagnostic accuracy for the identification of recurrent UC, particularly in patients with BC. Moreover, its accuracy outperforms C.I. for both BC and UTUC.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Zattoni F, Incerti E, Colicchia M, et al. Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study. Abdom Radiol (NY). 2018. PMID: 29302738. doi:10.1007/s00261-017-1443-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。